Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis

OBJECTIVE: Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naïve patients with spondyloarthritis (SpA) are lacking. The objectives were to compare treatment retention in biologics-naïve patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindström, Ulf, Glintborg, Bente, Di Giuseppe, Daniela, Nordström, Dan, Aarrestad Provan, Sella, Gudbjornsson, Bjorn, Askling, Johan, Lund Hetland, Merete, Aaltonen, Kalle, Krogh, Niels Steen, Geirsson, Arni Jon, Jacobsson, Lennart T H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827791/
https://www.ncbi.nlm.nih.gov/pubmed/31749988
http://dx.doi.org/10.1136/rmdopen-2019-001079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827791/
https://www.ncbi.nlm.nih.gov/pubmed/31749988
http://dx.doi.org/10.1136/rmdopen-2019-001079

Ejemplares similares